Prevalence ofN-Methyl-D-Aspartate Receptor Autoantibodies in the Peripheral Blood
Authors:
Open Access
- 1 July 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 71 (7) , 838-839
Abstract
In March 2013, we published a study in JAMA Psychiatry assessing the prevalence of anti–N-methyl-D-aspartate glutamate receptor (NMDAR) serum autoantibodies in unmedicated acutely ill patients with schizophrenia, major depression (MD), borderline personality disorder (BLPD), and healthy control individuals without neuropsychiatric disorder.1 The laboratory analyses of this set of samples were done in 2010. N-methyl-D-aspartate glutamate receptor antibodies were identified in 15 patients, primarily in those with a clinical diagnosis of schizophrenia (12 of 121, 9.9%) as opposed to those with MD (2 of 70, 2.9%), those with BLPD (0 of 38, 0%), and control individuals (1 of 230, 0.4%). Two patients were initially misdiagnosed as having catatonic or disorganized schizophrenia. Retrospectively, these cases were reclassified as cases with NMDAR encephalitis (presence of specific IgG anti-NR1a autoantibodies in both serum and cerebrospinal fluid).Keywords
This publication has 1 reference indexed in Scilit:
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011